SWK Holdings Corporation 9.00% Senior Notes due 2027
SWKHL scores 43.6 on the Conservative profile, blending a fundamental score (80% weight, emphasizing quality and stability (84% of fundamental weight)) with a machine-learning signal (20% weight) trained on 82 features across 30 years of data.
Net penalties of -32.9 points significantly impact the ranking. Without these adjustments, SWKHL would rank considerably higher.
These features are direct inputs to the machine learning model. The model was trained on these signals alongside 100 features (including 12 momentum/technical indicators) to produce the ML percentile score.
| Stock | Score | P/E | Rev Growth | Margin | Mkt Cap |
|---|---|---|---|---|---|
| SWKHL | 43.6 | 8.9 | 19.1% | 50.4% | $311M |
| CME | 86.4 | 27.2 | 9.9% | 57.5% | $114.0B |
| FHB | 84.9 | 11.8 | 3.2% | 24.2% | $3.1B |
| ACT | 84.5 | 8.9 | 2.4% | 54.6% | $6.1B |
| CINF | 84.2 | 10.7 | 11.4% | 18.9% | $25.4B |
| SEIC | 82.2 | 14.0 | 10.7% | 27.3% | $9.9B |
| TROW | 79.9 | 10.1 | 3.1% | 28.5% | $20.5B |
| QQQX | 79.7 | 10.4 | 48.6% | 257.3% | $1.4B |
| IBOC | 78.2 | 10.6 | 7.5% | 40.1% | $4.2B |
| HWC | 77.8 | 12.2 | -1.5% | 24.1% | $5.6B |
| FFIN | 77.5 | 18.8 | 11.7% | 30.7% | $4.7B |
| TRMK | 77.1 | 11.9 | 34.8% | 19.3% | $2.6B |
| NMIH | 77.1 | 7.7 | 8.4% | 55.1% | $3.0B |
| EWBC | 76.7 | 12.7 | 4.6% | 28.3% | $15.3B |
| WSFS | 76.3 | 12.8 | -3.1% | 21.1% | $3.5B |
| MCHB | 76.1 | N/A | 123.7% | 23.2% | $3.1B |
| Sector Average | 47.5 | 26.8 | 13.4% | -2.8% | — |
SWK Holdings Corporation, a specialty finance company that focuses on the healthcare sector. It operates in two segments, Finance Receivables and Pharmaceutical Development. The company provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors. It also offers non-discretionary investment advisory services to institutional clients in separately managed accounts to invest in life science finance. In addition, the company engages in the pharmaceutical development, formulation and manufacturing, and licensing business through the Peptelligence platform. Further, it intends to out-license its internal product pipeline to create novel formulations using its proprietary technology to develop treatments for patients and caregivers. The company was formerly known as Kana Software, Inc. and changed its name to SWK Holdings Corporation in December 2009. SWK Holdings Corporation was founded in 1996 and is headquartered in Dallas, Texas.
Stock is losing momentum near highs. The 200-day SMA is flattening or beginning to turn. Historically, this stage precedes distribution.
Stage 3 distribution — institutional selling pressure is building. Avoid new positions. If already holding, consider reducing and tightening stops below SMA50.
| Metric | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| Revenue | $11M | $10M | $12M | $12M |
| Gross Profit | $11M | $9M | $11M | $12M |
| Operating Income | $7M | $5M | $8M | $6M |
| Net Income | $9M | $4M | $5M | $6M |
| EPS (Diluted) | $0.72 | $0.29 | $0.37 | $0.47 |
| Gross Margin | 98.6% | 93.6% | 93.6% | 95.4% |
| Operating Margin | 61.3% | 46.1% | 68.6% | 44.7% |
| Net Margin | 80.7% | 35.2% | 38.4% | 47.5% |
This stock has limited trading volume and/or float. Institutional investors may face difficulty entering or exiting positions without significant price impact. A post-hoc penalty has been applied to the composite score (this is not a backtested model factor — it is a practical tradability overlay).
This stock has traded in a compressed range for 2 of the last 2 years (3-year range: 5.1%). Range-bound stocks may indicate limited upside potential. A -5pt penalty has been applied.
| Year | Low | High | Range | Status |
|---|---|---|---|---|
| 2024 | $24.65 | $25.88 | 4.9% | Narrow |
| 2025 | $24.60 | $25.87 | 5% | Narrow |
Growth estimates have been dampened based on technical and fundamental signals. This is a post-hoc adjustment to prevent overly optimistic projections for stocks showing declining momentum or deteriorating fundamentals.
Scores are generated by a multi-stage ML pipeline combining fundamental analysis, ensemble predictions, and structural risk signals. All data is for research purposes only and does not constitute financial advice. Past performance does not guarantee future results.